(0.51%) 5 214.08 points
(0.85%) 39 388 points
(0.27%) 16 346 points
(0.75%) $79.58
(5.44%) $2.31
(1.34%) $2 353.40
(3.41%) $28.54
(0.94%) $993.85
(-0.29%) $0.927
(-0.38%) $10.85
(-0.21%) $0.798
(0.88%) $92.54
Quarter results tomorrow
(bmo 2024-05-10)
Expected move: +/- 10.23%
@ $5.43
Išleistas: 9 vas. 2024 @ 22:55
Grąža: -48.07%
Ankstesnis signalas: vas. 7 - 21:00
Ankstesnis signalas:
Grąža: 5.44 %
Live Chart Being Loaded With Signals
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases...
Stats | |
---|---|
Šios dienos apimtis | 4 800.00 |
Vidutinė apimtis | 88 629.00 |
Rinkos kapitalizacija | 5.71M |
EPS | $0 ( 2024-04-01 ) |
Kita pelno data | ( $-2.18 ) 2024-05-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.0600 |
ATR14 | $0.0260 (0.92%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Sapirstein James | Sell | 174 | Common Stock |
2024-04-01 | Romano Sarah | Sell | 75 | Common Stock |
2024-03-15 | Sapirstein James | Sell | 1 887 | Common Stock |
2024-03-15 | Romano Sarah | Sell | 1 120 | Common Stock |
2024-03-13 | Syage Jack | Buy | 15 400 | Common Stock, par value $0.0001 per share |
INSIDER POWER |
---|
93.56 |
Last 95 transactions |
Buy: 5 900 618 | Sell: 1 318 677 |
Tūris Koreliacija
First Wave BioPharma, Koreliacija
10 Labiausiai teigiamai susiję koreliacijos | |
---|---|
PDSB | 0.826 |
ALLK | 0.815 |
VCSA | 0.815 |
NAKD | 0.811 |
WTBA | 0.81 |
FREE | 0.809 |
LBPS | 0.804 |
LYRA | 0.804 |
TRIT | 0.803 |
CRBU | 0.801 |
10 Labiausiai neigiamai susiję koreliacijos | |
---|---|
BBIO | -0.836 |
NVDA | -0.834 |
LSCC | -0.834 |
ACVA | -0.828 |
PDFS | -0.827 |
BRKS | -0.823 |
OSW | -0.822 |
FTNT | -0.821 |
ADI | -0.821 |
RRGB | -0.82 |
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
First Wave BioPharma, Koreliacija - Valiuta/Žaliavos
First Wave BioPharma, Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $-29 274.00 (0.00 %) |
EPS: | $-46.96 |
FY | 2023 |
Pajamos: | $0 |
Bruto pelnas: | $-29 274.00 (0.00 %) |
EPS: | $-46.96 |
FY | 2022 |
Pajamos: | $0 |
Bruto pelnas: | $-106 207 (0.00 %) |
EPS: | $-461.72 |
FY | 2021 |
Pajamos: | $0.00 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-1 377.25 |
Financial Reports:
No articles found.
First Wave BioPharma,
First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties; and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.